Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Shares of UK clinical stage drug development company Evgen Pharma (AIM: EVG) were down more than 8% at 2.94 pence mid-morning, after it revealed that JuvLife Ltd, a division of Juvenescence, has terminated the patent and know-how license agreement for Evgen's Sulforadex sulforaphane stabilization technology. 2 August 2023
Age-related and autoimmune disease specialist MyMD Pharmaceuticals has announced positive Phase II data for its oral TNF-α inhibitor, MYMD-1. 1 August 2023
Traders looked unfavorably on Apellis Pharmaceuticals stock on Monday, after the company's report into the safety of its newly-approved Syfovre (pegcetacoplan) detailed a small number of retinal vasculitis cases. 1 August 2023
The US Food and Drug Administration has dealt a blow to the market value of New Jersey, USA-based oncology company Citius Pharmaceuticals. 31 July 2023
Shares in US genetic medicines company Homology Medicines leapt more than 35% to $1.34 last Friday, after it revealed it has completed a review of its business, and the board of directors has approved a plan to evaluate strategic alternatives to maximize shareholder value. 31 July 2023
Shares of Ionis Pharmaceuticals closed up 3.3% at $39.79 on Friday, after the US RNA-targeted drug developer revealed it has expanded its existing collaboration with AstraZeneca to include exclusive rights for the UK pharma major to commercialize eplontersen in Latin America 31 July 2023
The US Food and Drug Administration (FDA) has granted approval of Balfaxar (prothrombin complex concentrate, human-lans) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, eg, warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. 26 July 2023
Swiss clinical-stage biotech AC Immune today announced the appointment of Nuno Mendonca as its new chief medical officer of the neurodegenerative diseases specialist. 26 July 2023
Shares in Stoke Therapeutics have fallen by a third after the company announced what it described as “positive new safety and efficacy data” from its early stage trial program for STK-001. 26 July 2023
Kodiak Sciences lost 47% of its stock market value on Monday after presenting top-line results from three Phase III studies of tarcocimab tedromer, an antibody biopolymer conjugate. 25 July 2023
Japanese pharma major Astellas Pharma today announced a research collaboration and license agreement with Kanagawa-based biotech firm PeptiDream to discover novel protein degraders for two targets selected by Astellas. 25 July 2023
Shares of Denmark-based vaccine developer Bavarian Nordic plummeted 21% to 148.80 Danish kroner yesterday, after it said it was discontinuing its RSV program. 25 July 2023
The US Food and Drug Administration (FDA) has approved Ycanth (cantharidin), a drug/device for the topical treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. 25 July 2023
Ireland-headquartered Horizon Therapeutics’ shares were barely changed in morning trading today, despite the company announcing after hours on Friday that its Phase II clinical trial evaluating daxdilimab for the treatment of systemic lupus erythematosus (SLE) did not show a statistically-significant separation between daxdilimab and placebo on the primary endpoint. 24 July 2023
Bicara Therapeutics, a biotech start-up founded in 2021 with the goal of developing dual-action biologics, has appointed David Raben as chief medical officer. 24 July 2023
US antibody-drug conjugates (ADCs) developer ImmunoGen today announced a multi-target license and option agreement to research novel, first-in-class ADCs with Canadian privately-held firm ImmunoBiochem Corp. 24 July 2023
The US Food and Drug Administration (FDA) has approved Cyfendus (anthrax vaccine adsorbed, adjuvanted), previously known as AV7909, developed by US biotech Emergent BioSolutions, whose shares closed up 8% on the news. 24 July 2023
San Diego, USA-based Turnstone Biologics has announced the pricing of its upsized initial public offering of 6,666,667 shares of common stock at a price to the public of $12.00 per share. 24 July 2023